BEMA Buprenorphine Phase 2 Study Results
Selected for Presentation at Pain Week 2010
August 30, 2010 08:03 AM Eastern Daylight Time
RALEIGH, N.C.--(EON: Enhanced Online News)--BioDelivery Sciences International, Inc. (Nasdaq:BDSI)
announced today that its abstract showing the results of a Phase 2 clinical study of BEMA Buprenorphine in the
treatment of pain has been selected for oral presentation at Pain Week 2010, a national conference educating
frontline clinicians who are faced with treating patients with pain. The presentation will take place on Friday,
September 10, as part of the 7:00 - 9:00 AM podium presentation session.
BDSI previously announced positive top-line results from the study which showed that BEMA Buprenorphine
demonstrated a statistically significant improvement compared to placebo in the primary efficacy endpoint, SPID-8
(sum of pain intensity differences at 8 hours; baseline observation carried forward analysis).
In addition, data will be presented which looked at a subset of patients with severe pain, where the analgesic efficacy
of BEMA Buprenorphine was more profound.
About BioDelivery Sciences International
BioDelivery Sciences (NASDAQ:BDSI) is a specialty pharmaceutical company that is leveraging its novel and
proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships
with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet
patient needs in the areas of pain management and oncology supportive care. BDSI’s pain franchise currently
consists of two products utilizing the Company’s patented BEMA buccal soluble film technology. ONSOLIS
(fentanyl buccal soluble film) was approved by FDA on July 16, 2009 for the management of breakthrough pain in
patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid
therapy for their underlying persistent cancer pain. The commercial rights to ONSOLIS are licen